Victory Capital Management
PHAS

Victory Capital Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Victory Capital Management’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,342
Closed -$8K – 3541
2020
Q1 		$8K Buy
+2,342
New +$10.7K ﹤0.01% 3175
2019
Q4 		– Sell
-2,630
Closed -$11K – 3525
2019
Q3 		$11K Buy
+2,630
New +$21K ﹤0.01% 3242

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Victory Capital Management's PHAS Position: Q2 2020 in Review

Victory Capital Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2020, closing a stake of 2,342 shares — an estimated $8K sold.

Victory Capital Management first reported a position in PHAS in Q3 2019 and held it in 2 quarters. The position peaked at $11K in Q3 2019. 60 funds tracked by Wall St. Rank hold PHAS as of Q2 2020.

  • Victory Capital Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 2,342 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $8K.
  • Victory Capital Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $11K in Q3 2019.
  • 60 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.